248 related articles for article (PubMed ID: 31057085)
1. Vasoactive Agents for Adult Septic Shock: An Update and Review.
Dalimonte MA; DeGrado JR; Anger KE
J Pharm Pract; 2020 Aug; 33(4):523-532. PubMed ID: 31057085
[TBL] [Abstract][Full Text] [Related]
2. Vasopressor weaning in patients with septic shock.
Arellano DL; Hanneman SK
Crit Care Nurs Clin North Am; 2014 Sep; 26(3):413-25. PubMed ID: 25169693
[TBL] [Abstract][Full Text] [Related]
3. Practice Patterns in the Initiation of Secondary Vasopressors and Adjunctive Corticosteroids during Septic Shock in the United States.
Bosch NA; Teja B; Wunsch H; Walkey AJ
Ann Am Thorac Soc; 2021 Dec; 18(12):2049-2057. PubMed ID: 33975530
[No Abstract] [Full Text] [Related]
4. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.
Jentzer JC; Coons JC; Link CB; Schmidhofer M
J Cardiovasc Pharmacol Ther; 2015 May; 20(3):249-60. PubMed ID: 25432872
[TBL] [Abstract][Full Text] [Related]
5. Vasopressors in Sepsis.
Colling KP; Banton KL; Beilman GJ
Surg Infect (Larchmt); 2018; 19(2):202-207. PubMed ID: 29336676
[TBL] [Abstract][Full Text] [Related]
6. A time-sensitive analysis of the prognostic utility of vasopressor dose in septic shock.
Chotalia M; Matthews T; Arunkumar S; Bangash MN; Parekh D; Patel JM
Anaesthesia; 2021 Oct; 76(10):1358-1366. PubMed ID: 33687732
[TBL] [Abstract][Full Text] [Related]
7. Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis.
Bauer SR; Sacha GL; Reddy AJ
Ann Pharmacother; 2020 Apr; 54(4):314-321. PubMed ID: 31679395
[No Abstract] [Full Text] [Related]
8. CT-proAVP IS NOT A GOOD PREDICTOR OF VASOPRESSOR NEED IN SEPTIC SHOCK.
Laribi S; Lienart D; Castanares-Zapatero D; Collienne C; Wittebole X; Laterre PF
Shock; 2015 Oct; 44(4):330-5. PubMed ID: 26196839
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations.
Sacha GL; Bauer SR; Lat I
Pharmacotherapy; 2019 Mar; 39(3):369-381. PubMed ID: 30644586
[TBL] [Abstract][Full Text] [Related]
10. Vasopressors and Inotropes in Sepsis.
Stratton L; Berlin DA; Arbo JE
Emerg Med Clin North Am; 2017 Feb; 35(1):75-91. PubMed ID: 27908339
[TBL] [Abstract][Full Text] [Related]
11. Vasopressor Therapy in the Intensive Care Unit.
Russell JA; Gordon AC; Williams MD; Boyd JH; Walley KR; Kissoon N
Semin Respir Crit Care Med; 2021 Feb; 42(1):59-77. PubMed ID: 32820475
[TBL] [Abstract][Full Text] [Related]
12. Continuation of Statin Therapy and Vasopressor Use in Septic Shock.
Zechmeister C; Hurren J; McNorton K
Ann Pharmacother; 2015 Jul; 49(7):790-5. PubMed ID: 25896127
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Vasopressor Duration in Septic Shock Patients With and Without Cirrhosis.
Durst MM; Eitzen EA; Benken ST
Ann Pharmacother; 2021 Aug; 55(8):970-979. PubMed ID: 33327736
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive drugs for vasodilatory shock in ICU.
Holmes CL; Walley KR
Curr Opin Crit Care; 2009 Oct; 15(5):398-402. PubMed ID: 19542884
[TBL] [Abstract][Full Text] [Related]
15. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials.
Vasu TS; Cavallazzi R; Hirani A; Kaplan G; Leiby B; Marik PE
J Intensive Care Med; 2012; 27(3):172-8. PubMed ID: 21436167
[TBL] [Abstract][Full Text] [Related]
16. Vasopressors to treat refractory septic shock.
Meresse Z; Medam S; Mathieu C; Duclos G; Vincent JL; Leone M
Minerva Anestesiol; 2020 May; 86(5):537-545. PubMed ID: 31994366
[TBL] [Abstract][Full Text] [Related]
17. Extensive variability in vasoactive agent therapy: a nationwide survey in Chinese intensive care units.
Pei XB; Ma PL; Li JG; Du ZH; Zhou Q; Lu ZH; Yun L; Hu B
Chin Med J (Engl); 2015 Apr; 128(8):1014-20. PubMed ID: 25881592
[TBL] [Abstract][Full Text] [Related]
18. Effect of norepinephrine on the outcome of septic shock.
Martin C; Viviand X; Leone M; Thirion X
Crit Care Med; 2000 Aug; 28(8):2758-65. PubMed ID: 10966247
[TBL] [Abstract][Full Text] [Related]
19. Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study).
Póvoa PR; Carneiro AH; Ribeiro OS; Pereira AC;
Crit Care Med; 2009 Feb; 37(2):410-6. PubMed ID: 19114885
[TBL] [Abstract][Full Text] [Related]
20. Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock.
Sacha GL; Lam SW; Duggal A; Torbic H; Reddy AJ; Bauer SR
Pharmacotherapy; 2018 Mar; 38(3):319-326. PubMed ID: 29328496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
